/AUPH
AUPH Stock - Aurinia Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$16.18+1.70%
+$0.27 (+1.70%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).42
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.63
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-4.2%upside
Target: $15.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AUPH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.02 – $16.34
TARGET (TP)$15.50
STOP LOSS$14.89
RISK/REWARD1:-0.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.44
52W High$16.48
52W Low$6.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $235.13M | $175.51M | $134.03M | $45.60M | $50.12M |
| Gross Profit | $206.88M | $161.37M | $128.37M | $44.51M | $50.12M |
| Gross Margin | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% |
| Operating Income | $-4,687,000 | $-91,691,000 | $-111,470,000 | $-180,735,000 | $-104,290,000 |
| Net Income | $5.75M | $-78,020,000 | $-108,180,000 | $-180,966,000 | $-102,680,000 |
| Net Margin | 2.4% | -44.5% | -80.7% | -396.8% | -204.9% |
| EPS | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 |
Company Overview
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$19
Average Target
↑ 16.2% Upside
Now
$15
Low
$19
Average
$25
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Leerink Partners | Downgrade | Market Perform | $16 |
| November 7th 2025 | Jefferies | Upgrade | Buy | $21 |
| November 5th 2025 | RBC Capital Mkts | Downgrade | Sector Perform | $15 |
| July 30th 2025 | H.C. Wainwright | Resumed | Buy | $17 |
| November 4th 2022 | Oppenheimer | Downgrade | Perform | - |
| May 5th 2022 | Cantor Fitzgerald | Resumed | Overweight | $25← $34 |
Earnings History & Surprises
AUPHBeat Rate
72%
Last 18 quarters
Avg Surprise
+69.4%
EPS vs Estimate
Beats / Misses
13/4
1 met exactly
Latest EPS
$0.23
Q4 2025
EPS Surprise History
Q2 24
+50.0%
$-0.07vs$-0.14
Q2 24
+82.4%
$-0.03vs$-0.17
Q3 24
+20.0%
$0.02vs$0.02
Q4 24
+566.7%
$0.10vs$0.01
Q1 25
+200.0%
$0.09vs$0.03
Q2 25
+100.0%
$0.16vs$0.08
Q3 25
-5.9%
$0.16vs$0.17
Q4 25
+43.8%
$0.23vs$0.16
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.21 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.16 | $0.23 | +43.8% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $0.17 | $0.16 | -5.9% | ✗ MISS |
Q2 2025 | May 12, 2025 | $0.08 | $0.16 | +100.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $0.03 | $0.09 | +200.0% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.01 | $0.10 | +566.7% | ✓ BEAT |
Q3 2024 | Aug 1, 2024 | $0.02 | $0.02 | +20.0% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.17 | $-0.03 | +82.4% | ✓ BEAT |
Q2 2024 | Apr 16, 2024 | $-0.14 | $-0.07 | +50.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.17 | $-0.09 | +47.1% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.18 | $-0.08 | +55.6% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.22 | $-0.18 | +18.2% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.27 | $-0.18 | +33.3% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.17 | $-0.06 | +64.7% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.27 | $-0.27 | 0.0% | = MET |
Q1 2022 | Feb 28, 2022 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-0.33 | $-0.39 | -18.2% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.36 | $-0.37 | -2.8% | ✗ MISS |
Latest News
Leerink Partners Downgrades Aurinia Pharmaceuticals to Market Perform, Raises Price Target to $16
➖ NeutralBenzinga•Dec 3, 2025, 01:33 PM
Jefferies Upgrades Aurinia Pharmaceuticals to Buy, Raises Price Target to $21
📈 PositiveBenzinga•Nov 7, 2025, 12:11 PM•Also:
RBC Capital Downgrades Aurinia Pharmaceuticals to Sector Perform, Raises Price Target to $15
➖ NeutralBenzinga•Nov 5, 2025, 12:36 PM
AUPH stock has given up its prior loss. Aurinia Pharmaceuticals shares were trading lower after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Nov 4, 2025, 05:31 PM
Aruinia discloses FDA information request on Lupkynis amid top regulator's exit
📉 NegativeSeeking Alpha•Nov 4, 2025, 05:30 PM
Aurinia Pharmaceuticals shares are trading lower after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
➖ NeutralBenzinga•Nov 4, 2025, 05:00 PM
Aurinia Pharmaceuticals Raises FY2025 Sales Guidance from $260.000M-$270.000M to $275.000M-$280.000M vs $270.478M Est
📈 PositiveBenzinga•Nov 4, 2025, 11:01 AM
Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.16 Estimate, Sales $73.468M Beat $67.418M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 11:00 AM
Aurinia Pharmaceuticals to Present New LUPKYNIS Data on Lupus Nephritis at ACR and ASN Conferences
📈 PositiveBenzinga•Oct 15, 2025, 10:02 AM
Aurinia responds after top FDA official's comment on lead drug
➖ NeutralSeeking Alpha•Sep 30, 2025, 11:08 AM
Reported Earlier, Aurinia Responds To Retracted LinkedIn Post, Stands Behind Full FDA Approval Of LUPKYNIS In Lupus Nephritis
📈 PositiveBenzinga•Sep 30, 2025, 06:33 AM
Frequently Asked Questions about AUPH
What is AUPH's current stock price?
Aurinia Pharmaceuticals Inc. (AUPH) is currently trading at $16.18 per share. The stock has moved +1.70% today.
What is the analyst price target for AUPH?
The average analyst price target for AUPH is $15.50, based on 1 analyst.
What sector is Aurinia Pharmaceuticals Inc. in?
Aurinia Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is AUPH's market cap?
Aurinia Pharmaceuticals Inc. has a market capitalization of $2.13 billion, making it a mid-cap company.
Does AUPH pay dividends?
No, Aurinia Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
IMCR
Immunocore Holdings plc
$36.01
Mkt Cap: $1.8B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
MNKD
MannKind Corporation
$5.84
Mkt Cap: $1.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
STOK
Stoke Therapeutics, Inc.
$31.96
Mkt Cap: $1.8B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
Explore stocks similar to AUPH for comparison